Humana Inc. (NYSE:HUM) Shares Purchased by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its holdings in shares of Humana Inc. (NYSE:HUM) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,103 shares of the insurance provider’s stock after purchasing an additional 81 shares during the quarter. Farther Finance Advisors LLC’s holdings in Humana were worth $533,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after acquiring an additional 37 shares during the period. Atlas Brown Inc. boosted its holdings in Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares during the period. Moors & Cabot Inc. boosted its holdings in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. Mather Group LLC. boosted its holdings in Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares during the period. Finally, Capital Advisors Ltd. LLC boosted its holdings in Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after acquiring an additional 43 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Up 0.5 %

NYSE:HUM opened at $253.11 on Monday. The firm has a market cap of $30.55 billion, a P/E ratio of 25.44, a PEG ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock’s 50 day simple moving average is $271.37 and its 200-day simple moving average is $279.50. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is currently 35.58%.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HUM shares. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, Barclays lifted their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.